Approval · Notice of Compliance 2223 · 2001
VASOTEC: Notice of Compliance 2223
Issued June 6, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2223
- Date
- June 6, 2001
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: use of vasotec in hypetensive pediatric patients
- Therapeutic class
- Angiotensin converting enzyme inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VASOTEC | Not yet assigned | — |
Medicinal ingredients
- ENALAPRIL MALEATE 2.5 MG per TAB
- ENALAPRIL MALEATE 5 MG per TAB
- ENALAPRIL MALEATE 10 MG per TAB
- ENALAPRIL MALEATE 20 MG per TAB